Plain-English translation of NCT06445114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating oropharyngeal cancer (cancer of the throat) after surgery. Instead of giving all patients the same dose of chemotherapy and radiation, doctors will use a blood test to measure circulating tumor DNA and combine that information with pathology results to create a personalized treatment plan. The goal is to give some patients less intensive treatment while still keeping them safe.
Standard treatment for this type of cancer can cause serious side effects. This trial exists to see whether a new blood test can help doctors identify which patients can safely receive lower doses of chemotherapy and radiation, while still preventing cancer from coming back.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have already had surgery to remove your tumor. You will then receive chemotherapy () given weekly through an IV, combined with radiation therapy to your throat and neck. The exact number of weeks of treatment—ranging from 3 to 5 weeks—and the radiation dose will depend on your personalized risk assessment based on your blood test results and tumor characteristics. You will have regular visits to monitor your health and side effects throughout treatment and during follow-up appointments after completion.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States